

XOLAIR (OMALIZUMAB) (PREFERRED) PRIOR AUTHORIZATION FORM

(form effective 1/9/2023)

Fax to PerformRxSM at **1-888-981-5202**, or to speak to a representative call **1-866-610-2774**.



PRIOR AUTHORIZATION REQUEST INFORMATION

<input type="checkbox"/> New request <input type="checkbox"/> Renewal request	Total # pages:	Name of office contact:
Contact's phone number:	LTC facility contact/phone:	

PATIENT INFORMATION

Patient name:	Patient ID #:	DOB:
Street address:	Apt. #:	City/state/zip:

PRESCRIBER INFORMATION

Prescriber name:	Specialty:	
State license #:	NPI:	MA Provider ID #
Street address:	Suite #:	City/state/zip:
Phone:	Fax:	

CLINICAL INFORMATION

Medication requested: <input type="checkbox"/> Xolair 150 mg/ml syringe <input type="checkbox"/> Xolair 150 mg vial <input type="checkbox"/> Xolair 75 mg/0.5 ml syringe <input type="checkbox"/> Xolair _____		
Dose/directions:	Quantity:	Duration: months
Diagnosis:	Dx code (required):	Weight: lbs / kg

PHARMACY INFORMATION (Prescriber to identify the pharmacy that is to dispense the medication, if applicable):

Deliver to: <input type="checkbox"/> Patient's Home <input type="checkbox"/> Physician's Office <input type="checkbox"/> Patient's Preferred Pharmacy Name:	
Pharmacy Phone #:	Pharmacy Fax #:
<input type="checkbox"/> I acknowledge that the patient agrees with the pharmacy chosen for delivery of this medication.	

HCPCS (HEALTHCARE COMMON PROCEDURE CODING SYSTEM) INFORMATION (if applicable):

Treatment setting: <input type="checkbox"/> Infusion Center <input type="checkbox"/> Home <input type="checkbox"/> Provider's Office <input type="checkbox"/> Hospital Outpatient Facility		
Facility name:	Facility NPI:	
J-code:	Number of units:	Date of service (MM/DD/YYYY):

INITIAL REQUESTS

1. Is Xolair being prescribed by or in consultation with a specialist? Yes – Provide specialty: _____ No
2. For a diagnosis of asthma: Is the patient being treated for moderate to severe allergen-induced asthma (allergic asthma confirmed by either a positive skin test or radioallergosorbent test) to an unavoidable perennial aeroallergen (e.g., pollen, mold, dust mite, etc.)? Yes – Submit documentation, including results of allergen reactivity test. No
3. For a diagnosis of asthma: Will Xolair be used in addition to standard asthma controller medications (e.g., inhaled corticosteroids, inhaled LABAs, etc.)?
 Yes – List medications being used: _____
 No
4. For a diagnosis of chronic idiopathic urticaria (CIU): Does the patient have a history of urticaria for a period of ≥ 6 weeks? Yes – Submit documentation. No
5. For a diagnosis of CIU: Does the patient require the use of systemic steroids to control urticarial symptoms? Yes – Submit documentation. No
6. For a diagnosis of CIU: Does the patient have a history of trial and failure, contraindication, or intolerance to an H1 antihistamine taken for at least 2 weeks? Check all that apply.
 Yes No
List medications tried or explain contraindication: _____

RENEWAL REQUESTS

1. For a diagnosis of asthma, has the patient experienced measurable evidence of improvement in asthma severity? Yes No
2. For a diagnosis of asthma, will Xolair continue to be used in addition to standard asthma controller medications (e.g., inhaled corticosteroids, inhaled LABAs, etc.)?
 Yes – List medications being used: _____
 No
3. Is Xolair being prescribed by or in consultation with a specialist?
 Yes – Provide specialty: _____
 No
4. For a diagnosis of chronic idiopathic urticaria, does the patient have documentation of improvement in symptoms and rationale for continued use of Xolair? Yes No
Provide rationale for continued use: _____

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION

Prescriber signature:	Date:
-----------------------	-------

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.